290 related articles for article (PubMed ID: 32630477)
1. A Review on Notch Signaling and Colorectal Cancer.
Tyagi A; Sharma AK; Damodaran C
Cells; 2020 Jun; 9(6):. PubMed ID: 32630477
[TBL] [Abstract][Full Text] [Related]
2. Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors.
Aste-Amézaga M; Zhang N; Lineberger JE; Arnold BA; Toner TJ; Gu M; Huang L; Vitelli S; Vo KT; Haytko P; Zhao JZ; Baleydier F; L'Heureux S; Wang H; Gordon WR; Thoryk E; Andrawes MB; Tiyanont K; Stegmaier K; Roti G; Ross KN; Franlin LL; Wang H; Wang F; Chastain M; Bett AJ; Audoly LP; Aster JC; Blacklow SC; Huber HE
PLoS One; 2010 Feb; 5(2):e9094. PubMed ID: 20161710
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic antibody targeting of individual Notch receptors.
Wu Y; Cain-Hom C; Choy L; Hagenbeek TJ; de Leon GP; Chen Y; Finkle D; Venook R; Wu X; Ridgway J; Schahin-Reed D; Dow GJ; Shelton A; Stawicki S; Watts RJ; Zhang J; Choy R; Howard P; Kadyk L; Yan M; Zha J; Callahan CA; Hymowitz SG; Siebel CW
Nature; 2010 Apr; 464(7291):1052-7. PubMed ID: 20393564
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic silencing of Notch signaling in gastrointestinal cancers.
Piazzi G; Bazzoli F; Ricciardiello L
Cell Cycle; 2012 Dec; 11(23):4323-7. PubMed ID: 23085543
[TBL] [Abstract][Full Text] [Related]
5. A computational guided, functional validation of a novel therapeutic antibody proposes Notch signaling as a clinical relevant and druggable target in glioma.
Herrera-Rios D; Li G; Khan D; Tsiampali J; Nickel AC; Aretz P; Hewera M; Suwala AK; Jiang T; Steiger HJ; Kamp MA; Muhammad S; Hänggi D; Maciaczyk J; Zhang W; Kahlert UD
Sci Rep; 2020 Oct; 10(1):16218. PubMed ID: 33004830
[TBL] [Abstract][Full Text] [Related]
6. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
7. Recent advances on NOTCH signaling in T-ALL.
Tzoneva G; Ferrando AA
Curr Top Microbiol Immunol; 2012; 360():163-82. PubMed ID: 22673746
[TBL] [Abstract][Full Text] [Related]
8. Force-induced unfolding simulations of the human Notch1 negative regulatory region: possible roles of the heterodimerization domain in mechanosensing.
Chen J; Zolkiewska A
PLoS One; 2011; 6(7):e22837. PubMed ID: 21829530
[TBL] [Abstract][Full Text] [Related]
9. The NOTCH signaling pathway: role in the pathogenesis of T-cell acute lymphoblastic leukemia and implication for therapy.
Tosello V; Ferrando AA
Ther Adv Hematol; 2013 Jun; 4(3):199-210. PubMed ID: 23730497
[TBL] [Abstract][Full Text] [Related]
10. Aspartate mutations in presenilin and gamma-secretase inhibitors both impair notch1 proteolysis and nuclear translocation with relative preservation of notch1 signaling.
Berezovska O; Jack C; McLean P; Aster JC; Hicks C; Xia W; Wolfe MS; Kimberly WT; Weinmaster G; Selkoe DJ; Hyman BT
J Neurochem; 2000 Aug; 75(2):583-93. PubMed ID: 10899933
[TBL] [Abstract][Full Text] [Related]
11. Notch oncoproteins depend on gamma-secretase/presenilin activity for processing and function.
Das I; Craig C; Funahashi Y; Jung KM; Kim TW; Byers R; Weng AP; Kutok JL; Aster JC; Kitajewski J
J Biol Chem; 2004 Jul; 279(29):30771-80. PubMed ID: 15123653
[TBL] [Abstract][Full Text] [Related]
12. Significance of NOTCH1 Expression in the Progression of Human Lung and Colorectal Cancers.
Vasileva MV; Khromova NV; Kopnin BP; Dugina VB; Kopnin PB
Biochemistry (Mosc); 2022 Oct; 87(10):1199-1205. PubMed ID: 36273888
[TBL] [Abstract][Full Text] [Related]
13. Significance of Notch and Wnt signaling for chemoresistance of colorectal cancer cells HCT116.
Kukcinaviciute E; Jonusiene V; Sasnauskiene A; Dabkeviciene D; Eidenaite E; Laurinavicius A
J Cell Biochem; 2018 Jul; 119(7):5913-5920. PubMed ID: 29637602
[TBL] [Abstract][Full Text] [Related]
14. The Notch pathway in colorectal cancer.
Vinson KE; George DC; Fender AW; Bertrand FE; Sigounas G
Int J Cancer; 2016 Apr; 138(8):1835-42. PubMed ID: 26264352
[TBL] [Abstract][Full Text] [Related]
15. Notch signaling, gamma-secretase inhibitors, and cancer therapy.
Shih IeM; Wang TL
Cancer Res; 2007 Mar; 67(5):1879-82. PubMed ID: 17332312
[TBL] [Abstract][Full Text] [Related]
16. Gamma-secretase inhibitor, a potential target therapy for MUC2-positive colorectal carcinoma.
Bu X; Li N; Tian X; Huang P
Neoplasma; 2011; 58(4):343-7. PubMed ID: 21520992
[TBL] [Abstract][Full Text] [Related]
17. Targeting notch signaling pathway in cancer: clinical development advances and challenges.
Takebe N; Nguyen D; Yang SX
Pharmacol Ther; 2014 Feb; 141(2):140-9. PubMed ID: 24076266
[TBL] [Abstract][Full Text] [Related]
18. Role of Notch signaling in colorectal cancer.
Qiao L; Wong BC
Carcinogenesis; 2009 Dec; 30(12):1979-86. PubMed ID: 19793799
[TBL] [Abstract][Full Text] [Related]
19. Notch-1 promotes stemness and epithelial to mesenchymal transition in colorectal cancer.
Fender AW; Nutter JM; Fitzgerald TL; Bertrand FE; Sigounas G
J Cell Biochem; 2015 Nov; 116(11):2517-27. PubMed ID: 25914224
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Notch1/Hes1 signaling pathway improves radiosensitivity of colorectal cancer cells.
Zhang H; Jiang H; Chen L; Liu J; Hu X; Zhang H
Eur J Pharmacol; 2018 Jan; 818():364-370. PubMed ID: 29126793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
